Aurora Cannabis launches localized European medical websites to deepen clinician and partner engagement

Aurora expands digital footprint in European medical markets

EDMONTON, Alberta, Feb 3 — Aurora Cannabis is launching four localized websites to bolster its presence in key European medical markets, the company says. The new central hub, www.auroramedicine.com, links to dedicated country pages for Germany, the United Kingdom and Poland, each presented in the native language of the market and tailored to local audiences. Aurora frames the move as part of a long-term strategy to increase growth and engagement across Europe by delivering a focused, locally relevant digital presence.

Targeted localized sites aim to deepen engagement

The sites are designed to improve engagement with healthcare professionals, commercial partners and prospective employees by highlighting Aurora’s science-backed approach and manufacturing expertise. Updated videos and photography emphasize quality, compliance and evidence-based processes while showcasing both Canadian-made products and local production footprints. Aurora positions the platforms as a streamlined resource that places products, scientific expertise and partnerships front and centre for medical audiences.

Andreas Dotterweich, senior vice president for Aurora Europe, frames the launch as demonstrable ongoing investment in what the company describes as its fastest-growing region. The company says the refreshed platforms align with its broader European communications strategy and provide enhanced resources for clinicians and partners seeking a trusted supplier amid evolving regulatory and clinical frameworks. Aurora signals the initiative is intended to reinforce market leadership and capture emerging opportunities as regulatory reforms and clinical adoption progress.

Broader corporate context

Aurora, a global medical cannabis company serving markets in Canada, Europe, Australia and New Zealand, emphasizes a medical-first approach and a strategic focus on higher-margin opportunities. Its portfolio includes brands such as Aurora®, MedReleaf®, Pedanios®, IndiMed™, San Raf®, Tasty’s™ and Whistler Cannabis Co™, and the company holds a controlling interest in Bevo Farms Ltd.

Operational aims and regulatory focus

The website initiative complements Aurora’s global brand evolution and supports recruitment, partnerships, regulatory engagement and patient access initiatives, the company says. Aurora stresses measurable commitments to local compliance, traceability and quality assurance, positioning the business to capitalise on anticipated European market expansion, regulatory reforms and increasing clinical adoption in the coming years.